Summary The effects of the diatomic radical, nitric oxide (NO), on melphalan-induced cytotoxicity in Chinese hamster V79 and human MCF-7 breast cancer cells were studied using clonogenic assays. NO delivered by the NO-releasing agent (C2H5)2N[N(O)NO]-Na+ (DEA/NO; 1 mM) resulted in enhancement of melphalan-mediated toxicity in Chinese hamster V79 lung fibroblasts and human breast cancer (MCF-7) cells by 3.6-and 4.3-fold, respectively, at the IC50 level. Nitrite/nitrate and diethylamine, the ultimate end products of DEANNO decomposition, had little effect on melphalan cytotoxicity, which suggests that NO was responsible for the sensitization. Whereas maximal sensitization of melphalan cytotoxicity by DEA/NO was observed for simultaneous exposure of DEA/NO and melphalan, cells pretreated with DEA/NO were sensitized to melphalan for several hours after NO exposure. Reversing the order of treatment also resulted in a time-dependent enhancement in melphalan cytotoxicity. To explore possible mechanisms of NO enhancement of melphalan cytotoxicity, the effects of DEANO on three factors that might influence melphalan toxicity were examined, namely NO-mediated cell cycle perturbations, intracellular glutathione (GSH) levels and melphalan uptake. NO pretreatment resulted in a delayed entry into S phase and a G/M block for both V79 and MCF-7 cells; however, cell cycle redistribution for V79 cells occurred after the cells returned to a level of cell survival, consistent with treatment with melphalan alone. After 15 min exposure of V79 cells to DEA/NO (1 mM), GSH levels were reduced to 40% of control values; however, GSH levels recovered fully after 1 h and were elevated 2 h after DEA/NO incubation. In contrast, DEANO (1 mM) incubation did not reduce GSH levels significantly in MCF-7 cells (approximately 10%). Melphalan uptake was increased by 33% after DEANNO exposure in V79 cells. From these results enhancement of melphalan cytotoxicity mediated by NO appears to be complex and may involve several pathways, including possibly alteration of the repair of melphalan-induced lesions. Our observations may give insights for improving tumour kill with melphalan using either exogenous or possibly endogenous sources of NO.
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Melphalan is a widely used chemotherapeutic agent for a variety of tumour types and is thought to exert its cytotoxic effect by alkylating and cross-linking DNA (Calabresi and Parks, 1985; Colvin and Chabner, 1990) . Although melphalan has shown efficacy alone or in combination with other chemotherapeutic agents, there remains a need to explore avenues to broaden its spectrum and effectiveness. Intracellular glutathione (GSH) levels have been shown to modulate melphalan cytotoxicity, and depletion of GSH by buthionine sulphoximine (BSO) has been shown to enhance melphalan cytotoxicity significantly (Green et al, 1984; Ozols et al, 1987) . Based on these preclinical findings, phase I clinical trials have been completed recently establishing a safe BSO dose to use in conjunction with melphalan (O'Dwyer et al, 1996) .
We have examined the effects of nitric oxide (NO) on the cytotoxicity of various agents and found that NO can modulate the cytotoxicity of various chemicals and ionizing radiation Wink et al, 1993; Laval and Wink, 1994; Liebmann et al, 1994) . NO is an endogenously produced radical that evokes a variety of physiological responses and has been postulated to function in the tumoricidal activity of the immune system (Hibbs et al, 1987; Stuehr and Nathan, 1989) . Furthermore, the enzyme nitric oxide synthase (NOS) has been shown to be expressed in various tumours (Asano et al, 1994; Fast et al, 1992; Fienstein et al, 1994; Lepoivre et al, 1994; Robbins et al, 1994; Thomsen et al, 1994) , an observation that suggests a potential endogenous source of this agent in vivo.
Because of the recent availability of chemical agents that can release NO (Maragos et al, 1991) and our recent findings that NO can enhance the cytotoxicity of BCNU , we have studied the effect of NO on the cytotoxicity of melphalan in Chinese hamster V79 lung fibroblasts and human breast cancer (MCF-7) cells. We report here that specific NO donor agents can significantly enhance the cytotoxicity of melphalan and may provide an interesting pharmacological approach for improving the clinical efficacy of melphalan.
MATERIALS AND METHODS Chemicals
DEA/NO {(C2H5)2N[N(O)NO]-Na+) was supplied by Dr J Saavedra and was prepared as previously described (Maragos et al, 1991) . Snitrosoglutathione (GSNO) was synthesized as described previously (Saville, 1958) . DEAINO stock solutions were made up in 0.02 N sodium hydroxide and the concentration was determined spectrophotometrically by using an extinction coefficient of 8000 M-l cm-' at its characteristic absorbance band (247 nm) . Hepes (N-[2-hydroxyethyl] piperazine-N'-[2-ethanesulphonic acid]) and melphalan were purchased from Sigma (St. Louis, MO, USA). L-buthionine sulphoximine (BSO) was purchased from Schweizerhall (South Plainfield, NJ, USA).
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Cell culture Chinese hamster V79 lung fibroblasts were cultured in F12 medium supplemented with 10% fetal calf serum and antibiotics. Human breast cancer cells (MCF-7) were obtained from Dr Ken Cowan (Medicine Branch, NCI, NIH, Bethesda, MD, USA) and were grown in RPMI medium (Gibco BRL Gathersburg, MD, USA) supplemented with 10% fetal calf serum and antibiotics. Cell survival was assessed by clonogenic assay; plating efficiencies for V79 and MCF-7 cells were 0.74 ± 0.1 and 0.52 ± 0.06 respectively. Stock cultures of exponentially growing cells were trypsinized, rinsed and plated (7x105 cells per dish) into a number of 100-cm2 Petri dishes and incubated for 16 h at 37°C before use in experimental protocols. Cells were exposed to varying concentrations of melphalan (0-4 jig ml-1) for 1 h. Final concentrations of DEA/NO or GSNO (1 mM) were added to parallel cultures immediately before addition of melphalan. In control studies, DEA/NO (1 mM) was allowed to decompose (denoted 'released DEAINO' on survival curves) in full medium ovemight at 37°C before cell exposure and added to parallel cultures immediately before addition of melphalan. GSNO (1 mM) was allowed to decompose (denoted 'released GSNO' on survival curves) in full medium by exposing the solution for 2 h at 365 nm UV (550 kJ m-2) (UV Transilluminator, UVP, San Gabriel, CA, USA) before cell exposure and added to parallel cultures immediately before addition of melphalan. GSNO decomposure was tested using the RSNO (thiolnitric oxide) assay described by Cook et al (1996) . For studies involving GSH depletion before DEA/NO and/or melphalan treatment, cells were pretreated with 0.5 mM BSO 15 h before experimental procedures as described above. For all treatment conditions, 10 mm Hepes was added to the medium such that the pH was maintained at 7.2. Following treatment, the cells were washed twice with phosphate-buffered saline (PBS), trypsinized, counted and plated for macroscopic colony formation. For each dose determination, cells were plated into triplicate dishes and each experiment was repeated a minimum of two times. Plates were incubated 7 or 10 days (V79, MCF-7 respectively), after which colonies were fixed with methanol-acetic acid (3:1), stained with crystal violet and counted. Colonies containing >50 cells were scored. Error bars represent sd of the mean and are shown when larger than the symbol. Survival curves were corrected for plating efficiency and cytotoxicity for DEA/NO or released DEAINO where appropriate.
For studies involved in pretreating cells with either DEAINO or decomposed DEA/NO for 1 h at 37°C and subsequently treating with melphalan, the pretreatment solution was removed and the cells were then rinsed twice with warm complete F12 medium, fresh medium added and then incubated at 37°C. As a function of time after DEAINO or released DEA/NO treatment, cells were treated with melphalan (final concentration of melphalan for V79 and MCF-7 cells was 1.5 and 2.0 jg ml-1 respectively) for 1 h at 37°C. Following melphalan exposure, cells were plated for survival assessment as described above. Additional studies were conducted in which the order of treatment was reversed.
Flow cytometry studies Cells were exposed to 1.0 mm DEA/NO (and released DEA/NO) for 1 h in a fashion identical to cell survival experiments described above. Following treatment, cells were rinsed twice, fresh medium added and incubated at 37°C. At various time intervals after treatment, cells from each treatment group were harvested and fixed in 70% ethanol and stored for DNA analysis. Fixed cells were incubated with 0.4 mg ml-' pepsin (Sigma) in 0.1 N hydrochloric acid for 30 min at 37°C. Cells were spun out of the pepsin and resuspended in 10 mm borate (pH 8.7) to increase the pH and centrifuged immediately. Finally, the samples were resuspended in PBS containing 10 ig ml-' propidium iodide (PI) to label DNA. Samples were analysed using an EPICS V cell sorter (Coulter Electronics, Hileah, FL, USA) using 488 nm for PI excitation and > 530 nm fluorescence for PI emission. DNA histograms were collected and stored using the CICERO software (Cytomation, Ft Collins, CO, USA). Cell cycle analysis was done using the Multicycle AV DNA/cell cycle analysis software (Phoenix Flow Systems, San Diego, CA, USA). The experiment was repeated twice.
Glutathione (GSH) measurements
Cells were treated with DEA/NO (1.0 mM) for 60 min at 37°C, rinsed twice, fresh medium added and incubated at 37'C. Control is quite stable and has a sensitivity range of 100 nm NO as previously reported Wink et al, 1995a) . and DEA/NO treated cells were sampled during and after DEAINO treatment. The samples (in triplicate) were prepared by rinsing the cell monolayer twice with cold PBS and then treating with 0.6% sulphosalicylic acid (4°C) for 5 min. Quadruplicate samples of each condition were assessed for GSH by the monobromobimane-HPLC method (Cook et al, 1991) . The total GSH levels for untreated V79 and MCF-7 cells were 1.1 and 31.9 fmol per cell respectively (Cook et al, 1991 
RESULTS

Effect of NO on melphalan cytotoxicity
Treatment of V79 cells with melphalan alone resulted in a concentration-dependent increase in cell killing, as shown in Figure IA . To determine the effects of NO on melphalan-mediated cytotoxicity, we used a member of the class of compounds known as NONOates (DEA/NO), which spontaneously release NO over a specific time period (Maragos et al, 1991) . DEA/NO treatment alone resulted in a 50% reduction in survival for V79 cells. Treatment of cells with 1.0 mm DEAINO simultaneously with varying concentrations of melphalan resulted in increased melphalan cytotoxicity ( Figure IA) . The enhancement in melphalan cytotoxicity by DEA/NO was approximately 3.6-and 2.2-fold at the IC50 and IC 9 levels respectively. Using 0.1 mM DEAINO, the enhancement factor for an IC 9 was 1.4 (data shown in Figure 4 , see below). In contrast, released DEA/NO, which showed no cytotoxicity to V79 cells alone, did not enhance melphalan cytotoxicity; in fact, modest protection was observed. The use of released DEA/NO was considered an important control because it evaluates if the decomposition products of DEA/NO (namely diethylamine and nitrite) could possibly effect melphalan cytotoxicity. As released DEA/NO did not enhance melphalan cytotoxicity, it can be concluded that NO released from DEA/NO enhanced the melphalan cytotoxicity. Similar findings were found for human MCF-7 cells as shown in Figure DEAINO treatment also enhanced melphalan cytotoxicity (enhancement at the IC50 was approximately 4.3), whereas released DEAINO had no effect on melphalan cytotoxicity.
DEA/NO and released DEA/NO treatment alone both resulted in a 60% reduction in survival for MCF-7 cells. Studies were next designed to determine the time course of enhanced melphalan cytotoxicity by DEAINO. For these studies, cells were first treated with DEA/NO or released DEAINO for 1 h. Following DEAINO pretreatment, cells were rinsed free of compound and incubated at 37°C in fresh medium. As a function of time after DEAINO treatment, cells were treated with a fixed concentration of melphalan for 1 h. Figure 2 shows for both V79 and MCF-7 cells that the enhanced melphalan cytotoxicity seen for simultaneous treatment with DEAINO and melphalan ( Figure 1) was also observed following DEA/NO treatment. For V79 cells enhancement of melphalan-induced cell killing by DEAINO persisted (although not to the extent observed for simultaneous treatment) for at least 30 min, after which there was a steady increase in survival that by 240 min approached that of melphalan treatment alone (Figure 2A ). Pretreatment with released DEA/NO did not significantly enhance melphalan cytotoxicity throughout the time course. Figure 2B illustrates qualitatively similar findings for MCF-7 cells. For MCF-7 cells, enhancement of melphalan cytotoxicity was observed throughout the time course studied.
Enhancement was greatest from 0 to 120 min after DEA/NO treatment and then there was a gradual increase in survival that came near but never actually reached the melphalan-alone survival level by 450 min. Released DEAJNO treatment did not exert effects on melphalan cytotoxicity ( Figure 2B ). Collectively, the data in Figures 1 and 2 show that, although melphalan cytotoxicity was enhanced by simultaneous DEAINO treatment, enhancement could also be observed for considerable time after DEA/NO treatment. With time, the enhancement in melphalan cytotoxicity by DEA/NO pretreatment diminishes, which was variable according to cell type. Melphalan cytotoxicity has been shown to exhibit cell cycle dependency (Meyn and Murray, 1986) . To determine if DEAINO treatment imposed any perturbations in the cell cycle of V79 or MCF-7 cells that might influence subsequent melphalan cytotoxicity, flow cytometry studies were conducted. Figure 3 shows the DNA flow cytometry results for V79 cells treated with 1 mm DEA/NO for 1 h then washed and followed for times up to 7 h. No major changes in the cell cycle were observed until 5 h, when the cell cycle distributions indicated a delayed entry into S-phase ( Figure 3F ). This synchronous entry into and through S-phase would indicate that the cells must have been delayed at a specific point at the G1/S border. In addition, GI continued to decrease and G2JM continued to increase after 5 h (Table 1) , which indicates that a G2/M block must also have occurred. Released DEA/NO had no effect on the cell cycle of any time points examined (data not shown). Thus, NO released by DEAINO has profound cell cycle effects, but these effects do not begin to become evident until 5 h after DEA/NO treatment. The MCF-7 cells treated with DEAINO responded in a similar fashion. A decrease in G1 and a synchronous increase in S was observed after 7 h; however, the effect was much reduced compared with V79 cells (Figure 4 and Table 2 ).
Experiments were next conducted where the order of DEA/NO or released DEA/NO and melphalan treatments were reversed. As shown in Figure 5 , if melphalan treatment preceded DEAINO treatment, time-dependent enhancement in melphalan cytotoxicity was observed for both cell lines similar to that shown in Figure 2 .
A different type of NO-releasing agent was next evaluated. GSNO, a S-nitrosothiol NO donor agent, did not modify melphalan cytotoxicity in V79 cells, as shown in Figure 6 . GSNO treatment alone resulted in no cytotoxicity. Likewise, decomposed GSNO was not cytotoxic alone and had no influence on melphalan cytotoxicity.
Effects of DEA-NO treatment on intracellular GSH levels
As depletion of intracellular GSH levels has been shown to enhance the cytotoxicity of melphalan (Green et al, 1984; Ozols et al, 1987) , we conducted experiments to determine if DEA/NO treatment lowered GSH levels. Table 3 shows that a 15-min exposure to DEA/NO reduced GSH levels in V79 cells by approximately 60%; however, after 60 min GSH levels had returned to control levels, and by 120 min there was a substantial increase in GSH levels (205% of control). In contrast, DEAINO treatment did not significantly alter GSH levels in MCF-7 cells (approximately 10% at 15 min) ( Table 3) .
Effects of DEAINO treatment on melphalan uptake
The enhancement of melphalan cytotoxicity by DEAINO might result from increased cellular uptake of melphalan. To explore this possibility, V79 cells were treated with radiolabelled melphalan in the absence or presence of 1 mm DEA/NO or released DEA/NO for 1 h (culture conditions identical to cytotoxicity experiments cited above). Melphalan uptake for control, DEAINO and released DEA/NO treatments was 754 ± 98, 1000 ± 73, and 791 ± 91 d.p.m. respectively. DEAINO treatment resulted in a significant increase (approximately 33%) in melphalan uptake (P < 0.01), whereas released DEA/NO treatment had no significant effect on melphalan uptake.
British Journal of Cancer (1997) 76(3) Comparison of BSO and DEA/NO treated cells
Because GSH is known to modulate melphalan cytotoxicity (Green et al, 1984; Ozols et al, 1987) , we studied the interaction of DEA/NO with another GSH-depleting agent, BSO. V79 cells were incubated with 0.5 mm BSO for 15 h and then incubated with various concentrations of melphalan (Figure 7 ). BSO treatment alone was not cytotoxic. Treatment with 0.5 mm BSO reduced GSH levels to < 5% of control values and substantially increased melphalan cytotoxicity, which is consistent with previous reports Melphalan (gg ml-') Figure 7 Survival of V79 cells exposed to varying concentrations of melphalan for 1 h in the absence of presence DEANO (0.1 mM) or BSO (0.5 mm, 15 h pretreatment) treated cells (Green et al, 1984; Ozols et al, 1987) . The enhancement ratio at the IC 9 was 3.7. Because BSO increases DEA/NO cytotoxicity, 0.1 mM DEA/NO was used for the melphalan studies. This concentration of DEA/NO, which releases lower amounts of NO (see Figure 8 below), increased the melphalan cytotoxicity with an enhancement ratio at the IC 9 of 1.4. Combining 0.1 mM DEA/NO with BSO further increased the melphalan sensitization compared with BSO alone (enhancement ratio at the ICg, of approximately 4.9).
No chemistry of NO donor compounds A NO-sensitive electrode was used to determine NO concentrations as a function of time, resulting from NO donor agents under conditions similar to cell survival studies (Wink et al, 1995b) .
British Journal of Cancer (1997) Time (s) Figure 8 Electrochemical determination of NO concentrations during 1 h exposure DEA/NO (1.0 and 0.1 mM) and 1.0 mm GSNO in cell culture media using a NO-sensitive electrode. Figure 2A) . MCF-7 cells showed a qualitiatively similar cell cycle profile after DEA/NO treatment; however, these cells had not returned to the melphalan treatmentalone survival level by 450 min. The reason for the differences in the two cell types is not clear. These data support the notion that DEA/NO treatment inhibits the repair of melphalan damage. To test this hypothesis further, we conducted experiments in which the order of melphalan and DEA/NO treatments were reversed ( Figure 5 ). Here again, DEA/NO enhanced melphalan cytotoxicity initially, followed by a gradual return to melphalan-alone cytotoxicity survival levels. These data argue against cell cycle effects playing a major role in the observed NO-mediated enhancement of melphalan cytotoxicity. Two factors in the NO-mediated enhancement of melphalan cytotoxicity were studied: GSH levels and melphalan uptake. First, the effects of DEAINO on intracellular GSH levels were evaluated. Modulating GSH levels has been demonstrated to influence melphalan cytotoxicity (Green et al, 1984; Hamilton et al, 1985; Russo et al, 1986; Kramer et al, 1987; Ozols et al, 1987; Skapek et al, 1988; Canada et al, 1993) . GSH depletion by BSO enhances melphalan cytotoxicity. The presence of NO in an aerobic environment has been shown to reduce GSH levels (Walker et al, 1995) . It has been demonstrated in chemical studies that reactive nitrogen oxide species (RNOS), formed from the NO/O2 reaction, react rapidly with GSH to form GSNO Walker et al, 1995) . As 1 mm DEA/NO treatment reduced GSH levels in V79 cells by 60% within 15 min, it might be assumed that either the reduction in GSH or the intracellular formation of GSNO may contribute to the increased melphalan cytotoxicity. Several points, however, contradict that conclusion; (1) GSH levels recovered to control levels by 1 h and by 2 h actually superseded control GSH levels (Table 3) , and (2) GSNO added extracellularly did not enhance melphalan cytotoxicity. With respect to the first point, melphalan cytotoxicity was still increased by 2 h even though the GSH levels were 205% of control. Furthermore, cells that were previously depleted of GSH by BSO were still sensitized to melphalan by DEA/NO (Figure 7) . Although the sensitization was not completely additive, the result suggests that NO sensitizes cells to melphalan by a pathway that may be independent of GSH. Finally, MCF-7 cells were also sensitized to melphalan even though very little GSH was depleted by DEA/NO (Table 3) .
We next determined if DEAINO treatment could affect the cellular uptake of melphalan. Exposure of V79 cells to DEA/NO resulted in approximately 33% increase in melphalan uptake. The increase in melphalan uptake caused by the DEAINO treatment could not account in a one-to-one fashion for all the melphalan enhancement as the DEA/NO modification factor was greater than 30% (Figure 1) . Although DEA/NO incubation does increase intracellular melphalan levels, the increase may only explain a portion of the enhanced cytotoxicity; however, we cannot exclude the possibility that the 30% increase in uptake is responsible for the sensitization of melphalan by NO. However, reversing the order of treatment (see Figure 5 ) also resulted in enhanced melphalan cytotoxicity. This would rule out altered melphalan uptake as a mechanism of enhanced cytotoxicity.
Although not conclusive, the data presented in this study suggest that NO treatment may inhibit melphalan damage repair. One of the primary repair mechanisms for alkylating agents is DNA repair. It has been shown that exposure of cells to millimolar concentrations of DEAINO inhibits specific DNA repair proteins in intact cells . The inhibition of these proteins has been shown to be mediated by RNOS . Although not all repair proteins are affected by NO or RNOS, those which possess rich thiol regions such as zinc finger motifs can be inhibited (Kroncke et al, 1994; Misra et al, 1995; Schwarz et al, 1995) . In fact, DEA/NO treatment results in loss of activity to such proteins, even in whole cells . Thus, a possible mechanism for NO enhanced melphalan cytotoxicity is that RNOS formed by DEA/NO exposure results in damage to repair systems that subsequently inhibit the repair of melphalan induced DNA damage. Whatever the actual mechanism(s) of NO-induced sensitization of cells to treatment with melphalan, our results show a potential avenue to improve melphalan efficacy.
